Cue Biopharma (NASDAQ:CUE – Get Free Report) is set to announce its earnings results after the market closes on Monday, August 19th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.
Cue Biopharma Stock Performance
CUE opened at $0.63 on Wednesday. The firm’s fifty day simple moving average is $1.03 and its two-hundred day simple moving average is $1.62. Cue Biopharma has a 52-week low of $0.62 and a 52-week high of $3.25. The company has a market cap of $30.84 million, a price-to-earnings ratio of -0.60 and a beta of 1.96. The company has a quick ratio of 2.47, a current ratio of 2.47 and a debt-to-equity ratio of 0.11.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. JMP Securities reduced their price target on shares of Cue Biopharma from $15.00 to $2.00 and set a “market outperform” rating for the company in a research report on Friday, July 26th. Piper Sandler cut their price objective on Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cue Biopharma has a consensus rating of “Buy” and an average price target of $5.80.
About Cue Biopharma
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
Featured Stories
- Five stocks we like better than Cue Biopharma
- Energy and Oil Stocks Explained
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
- Investing in Travel Stocks Benefits
- Hut 8 Corp.’s Earnings: Is Crypto Mining About to Change?
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.